Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice

Clinical and Experimental Allergy

Volumn 30, Issue 7, 2000, Pages 1024-1032

  Rask, C ^b   Holmgren, J ^b,c   Fredriksson, M ^b   Lindblad, M ^b   Nordstrom I ^b   Sun, J B ^b   Czerkinsky, C ^a,b  

^a INSERM   (France)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Department of Medical Microbiology ^*  (Sweden)

Author keywords

Allergy; Cholera toxin B subunit; Immunoglobulin E; Immunotherapy; Oral tolerance; Ovalbumin

Indexed keywords

ALLERGEN; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG CONJUGATION; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TH1 CELL;

ADMINISTRATION, ORAL; ALLERGENS; ANIMALS; CHOLERA TOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPERSENSITIVITY, IMMEDIATE; ICE; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN E; IMMUNOTOXINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOUTH MUCOSA; OVALBUMIN; PASSIVE CUTANEOUS ANAPHYLAXIS; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES;

EID: 0043129198     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2000.00849.x     Document Type: Article

References (56)

1. 1 Wells H. Studies on the chemistry of anaphylaxis III. Experiments with isolated proteins, especially those of hen's egg. J Infect Dis 1911; 9:147-71.
2. 2 Chase MW. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc Soc Exp Biol 1946; 61:257-9.
3. 3 Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U. Clinical and immunological responses to oral and subcutaneous immunotherapy with grass pollen extracts. Eur J Pediatr 1982; 138:341-4.
4. 4 Wortmann F. Oral hyposensitization of children with pollinosis or house dust asthma. Allergol Immunopathol 1977; 5:15-26.
5. 5 van Halteren AG, van der Cammen MJ, Cooper D, Savelkoul DF, Kraal G, Holt PG. Regulation of antigen-specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction. J Immunol 1997; 159:3009-15.
6. 6 Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259:1321-4.
7. 7 Lider D, Santos LLMB, Lee CSY, Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. J Immunol 1989; 142:748-52.
8. 8 Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F, Lider O, Weiner HL. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990; 144:1689-95.
9. 9 Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44:209-14.
10. 10 Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988; 112:364-70.
11. 11 Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986; 83:7443-6.
12. 12 Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994; 91:6688-92.
13. 13 Chen Y, Inobe JI, Kuchroo VK, Baron JL, Janeway CA, Jr Weiner HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996; 93:388-91.
14. 14 Inobr JI, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998; 28:2780-90.
15. 15 McKenzie SJ, Halsey JF. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 1984; 133:1818-24.
16. 16 de Aizpura HJ, Russel-Jones GJ. Oral vaccination: Identification of classes of proteins that provoke immune response upon oral feeding. J Exp Med 1988; 167:440-51.
17. 17 Czerkinsky C, Russel MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Inf Imm 1989; 57:1072-7.
18. 18 Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral - mucosal adjuvant and antigen vector systems. Vaccine 1993; 11:1179-84.
19. 19 Bergquist C, Lagergård T, Lindblad M, Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Inf Imm 1995; 63:2021-5.
20. 20 Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91:10795-9.
21. 21 Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996; 93:7196-201.
22. 22 Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Holmgren J, Thivolet C. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94:4610-4.
23. 23 Challacombe SJ, Tomasi TB. Systemic tolerance and secretory immunity after oral immunization. J Exp Med 1980; 152:1459-72.
24. 24 Lebens M, Johansson S, Osek J, Lindblad M, Holmgren J. Large-scale production of Vibrio cholera toxin B subunit for use in oral vaccines. Biotechn 1993; 11:1574-8.
25. 25 Sanchez J, Holmgren J. Recombinant system for overproduction of cholera toxin B subunit in Vibrio cholera as a basis for vaccine development. Proc Natl Acad Sci USA 1989; 86:481-5.
26. 26 Svennerholm AM, Holmgren J. Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbant assay (GM1-ELISA) procedure. Curr Microbiol 1978; 1:19-23.
27. 27 Ovary Z. Passive cutaneous anaphylaxis. In: Ackroyd JF. eds. Immunological Methods. Oxford: Blackwell Scientific Publications, 1964; 259-84.
28. 28 Watanabe N, Ovary Z. Antigen and antibody detection by in vivo methods; A re-evaluation of passive cutaneous anaphylactic reactions. J Immunol Meth 1977; 14:381-90.
29. 29 Mowat AM, Strobel S, Drummond HE, Ferguson A. Immunological responses to fed protein antigens in mice. I. Reversal of tolerance to ovalbumin by cyclophosphamide. Immunology 1982; 45:105-13.
30. 30 Gieni RS, Yang X, Hayglass KT. Allergen-specific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergens. J Immunol 1993; 150:302-10.
31. 31 Tamura SI, Hatori E, Tsuruhara T, Aizawa C, Kurata T. Suppression of a delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escerichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 1997; 15:225-9.
32. 32 Leishman AJ, Garside P, Mowat AM. Immunological consequences of intervention in established immune responses by feeding protein antigens. Cell Immunol 1998; 183 (2):137-48.
33. 33 Akdis GA, Blesken T, Akdis M, Alkan SS, Heusser CH, Blaser K. Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro. Eur J Immunol 1997; 27:2351-7.
34. 34 Zieg G, Lack G, Harbeck RJ, Gelfand EW, Leung DYM. In vivo effects of glucocortoicoids on IgE production. J Allergy Clin Immunol 1994; 94:222-30.
35. 35 Bohle B, Willheim M, Baier K, Stadler B, Sitzauer S, Scheiner O, Kraft D, Ebner C. Hydrocortisone enhances total IgE levels - but not the synthesis of allergen-specific IgE - in a monocyte-dependent manner. Clin Exp Immunol 1995; 101:474-9.
36. 36 Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 101:1067-71.
37. 37 Curtis H. The immunizing cure of hay fever. Med News 1900; 74:16-8.
38. 38 Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572-3.
39. 39 van Metre TE, Marsh DG, Adkinson NF, Kagey-Sobotka A, Khattignavong A, Norman PS, Rosenberg GL. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82:1055-68.
40. 40 Norman PS, van Metre TE. The safety of allergenic immunotherapy. J Allergy Clin Immunol 1990; 85:522-5.
41. 41 Goldstein MF, Dvorin DJ, Dunsky EH, Lesser RW, Heuman PJ, Loose JH. Allergy grand rounds. Allergic Rhizomucor sinusitis. J Allergy Clin Immunol 1992; 90:394-7.
42. 42 Giovane AL, Bardare M, Passalacqua G, Ruffoni S, Scordamaglia A, Ghezzi E, Canonica GW. A 3-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994; 24:53-9.
43. 43 Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49:309-13.
44. 44 Litwin A, Flanagan M, Entis G, Gottschlich G, Esch R, Gartside P, Michael JG. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997; 100:30-8.
45. 45 Garside P, Steel M, Worthey EA, Satoskar A, Alexander J, Bluethmann H, Liew FY, McI, Mowat A. T helper 2 cells are subjected to high dose oral tolerance and are not essential for its induction. J Immunol 1995; 154:5649-55.
46. 46 McSorley SJ, Rask C, Pichot R, Julia V, Czerkinsky C, Gleichenhaus N. Selective tolerization of Th-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur J Immunol 1998; 28:424-32.
47. 47 Tarkowski A, Sun J-B, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum 1999; 42:1628-34.
48. 48 Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol 1993; 23:935-42.
49. 49 Melamed D, Friedman A. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. Eur J Immunol 1994; 24:1974-81.
50. 50 de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995; 27:537-41.
51. 51 Wiedermann U, Jahn-Schmid B, Lindblad M, Rask C, Holmgren J, Kraft D, Ebner C. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the allergen in a murine model of type I allergy. Int Immunol 1999; 11:1717-24.
52. 52 McMenamin C, Pimm C, McKersey M, Holt PG. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells. Science 1994; 265:1869-71.
53. 53 Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991; 174:791-8.
54. 54 Holt PG, McMenamin C. Defence against allergic sensitization in the healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989; 19:255-62.
55. 55 Yamamoto M, Fujihashi K, Kawabata K, McGhee J, Kiyono H. A mucosal intranet: Intestinal epithelial cells down-regulate intraepithelial, but not peripheral, T cell lymphocytes. J Immunol 1998; 160:2188-96.
56. 56 Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. New England J Med 1989; 320:271-7.